
usd aug pm et
summari second largest distributor pharmaceut broad rang
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
may pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
lift target
fy sep ep forecast --
histor forward price-to-earnings averag due
materi litig risk rais fy ep
estim
jun-q ep vs
yoy beat consensu jun-q revenu
grew yoy strong demand specialti
held firm yoy second quarter row
posit sign
much character
compress margin driven sever gener
per share yoy
materi outpac revenu growth
appli debt reduct
share repurchas boost per
share earn see limit abil
expand margin due downstream
consolid drug suppli chain
improv custom purchas power
expect ep grow modestli steadi sale
risk assess reflect view strong
long-term growth prospect drug distributor volum
age develop popul expand health
care coverag emerg market drive growth
prescript volum also think barrier entri
industri high due nation three largest
distributor possess market share
posit balanc view
extrem limit abil rais price current
environ custom consolid polit
pressur drug price increas competit
gener manufactur industri persist
fiscal year end sep ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
execut vice-president chief
corpor overview amerisourcebergen corpor second largest pharmaceut
distribut compani primari busi entail wareh logist servic
connect manufactur brand-nam gener pharmaceut end-us outlet downstream
custom includ wide varieti retail mail-ord pharmaci hospit network outpati
facil also offer value-ad servic pharmaci manag consult inventori
manag softwar drug commerci servic manufactur group purchas servic
physician practic
also occupi strong posit specialti pharmaceut distribut typic inject infus
drug especi oncology-rel servic specialti busi histor achiev faster
organ growth higher margin convent drug distribut busi
continu case futur year expect sale growth complex biolog drug significantli
outpac convent drug
custom concentr import awar ten largest account total
revenu fy sale two largest custom
script esrx account revenu respect
market profil return wareh logist inventori data servic drug distribut
contract typic pay distributor negoti percentag purchas order amount
multi-year period actual drug price usual negoti manufactur pharmaci
benefit manag arrang leav distributor price negoti elimin
price power view rise drug price typic lead larger whole dollar servic fee
distributor revers true drug price declin drug inflat also help distributor
tradit resal arrang purchas bulk inventori manufactur resel
downstream custom gain spread increas lower-cost exist inventori sold new
increas access health insur especi global middl class expand age develop
market popul posit long-term driver pharmaceut volum view drug
price critic factor profit recent year low price inflat brand drug
gener deflat result lower distribut fee negat postiv impact higher volum
distributor see shrink profit margin drug inflat keep pace rise
big pharmaceut distributor
form gener drug sourc joint ventur jv larg retail pharmaci began
collabor jv improv bargain power gener manufactur
similar jv walgreen respect three jv repres
three largest pharmaceut distributor retail pharmaci chain
increas bargain power jv manufactur like factor gener price
deflat trend last sever year contribut slower sale growth convent
pharmaceut turn led distributor seek higher growth margin non-tradit
drug busi specialti pharmaceut medic suppli
corpor strategi focus expand convent specialti pharmaceut
distribut busi recent expans busi includ pharmedium
lead provid specialti product acut care hospit acquir novemb
januari acquisit smith formerli largest privat held drug
distributor
also enter strateg relationship wherebi
becam primari distribut resourc intern pharmaci compani return
grant warrant purchas stake gradual increas ownership roughli
novemb sinc launch relationship fy revenu growth materi exceed
competitor fy particularli activ driven addit
distribut busi see potenti risk move forward howev independ pharmaci
may ultim steer busi away avoid send profit larg competitor
competit landscap price breadth product offer value-ad servic program
primari competit factor drug distribut industri big domin larg
multi-year contract consolid amongst downstream custom major impact
distributor earn case gain busi
pharmaci chain sold store prior transact rival provid
distribut servic store
financi trend fy achiev three-year compound annual growth rate
revenu adjust pre-tax incom per share adjust pre-tax incom margin around
fy fy per share earn growth aid roughli million net
share buyback fy view balanc sheet strong cash billion
decemb ebita-to-interest coverag
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli under-valued usd
bullish sinc may technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
distributor sub-industri next
month neutral driven mix posit
neg factor posit side
expect distribut revenu receiv
tailwind growth prescript drug
volum higher brand drug price
pharmaceut industri see slowdown
patent expir neg side
think profit margin continu
pressur on-going consolid drug
suppli chain focu mainli drug
distribut busi gener
revenu health care distributor
prescript drug demand like continu
increas turn drive
greater volum handl distributor
forecast primari factor rise drug
demand age babi boomer
prime health care util year gain
 health-insur popul
everi day age cohort grow
time fast total popul
base latest data avail censu
gov expect growth increas
prescript drug demand senior tend
health care need younger
addit recent censu gov data
indic health-insur
popul continu grow net
million individu ad health plan
view peopl health
insur like prescript
written fill uninsur due
manag cost insur doctor
visit drug expect growth
health-insur popul continu
year ahead strong labor market
especi full-tim employ pull
averag first six month
acceler averag growth
period
care distributor tend benefit
rise drug price addit volum
expect brand drug price support
favor period patent expir
year ahead data evaluatepharma
indic annual global drug sale risk
expir patent averag total
 forecast drop
fewer patent cliff
year ahead like posit
brand drug price turn drive higher
revenu distributor typic
collect percentag drug price
wareh ship data track
unfortun distributor expect
posit factor outlin
negat grow scale
player drug suppli chain major
consolid drug maker upstream
distributor well pbm pharmaci
insur downstream on-going
potenti respons
increas risk new regul drug
industri consolid wave increas
negoti power supplier
custom health care distributor
like limit abil drive price increas
margin improv year ahead
analysi
 year-to-d
juli health distributor
rose gain
base index
five-year market price perform aug
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
amerisourcebergen corpor cut target
price-to-earnings multipl ntm ep forecast lower fy
sep ep estim fy jun-q ep
beat estim howev view result favor
appli substanti discount forward price-to-earnings multipl sever reason first
view yoy revenu growth quarter sustain due
debt-fund acquisit largest custom major factor
second top-lin growth translat oper earn growth margin
pressur gener drug price deflat doesnt look like let anytim
soon third think interest debt use fund acquisit employe
sever restructur cost includ oper earn
better assess growth factor account oper incom
quarter fell yoy rather remain flat report /colin scarola
et cfra keep hold opinion share
lower target price assum
forward ev/ebitda near high end trade rang
believ justifi potenti industri consolid despit
earn growth pressur see intens price competit slow
brand gener drug price inflat mar-q adjust ep vs
estim revenu grew estim
benefit recent acquisit growth largest custom
initi benefit complet
on-board retail pharmaci follow acquisit rite aid
store walgreen march margin narrow less expect benefit
recent acquisit stabil gener drug inflat rate
despit pressur suspens oper pharmedium
memphi distribut center expect becom fulli oper
fy sep /joseph agnes
analyst research note compani news
pm et cfra keep hold recommend share
corpor lift target fy
sep ep forecast -- histor forward price-to-earnings averag due
materi litig risk rais fy ep estim
jun-q ep vs yoy beat consensu
jun-q revenu grew yoy strong demand specialti
pharmaceut adjust oper margin held firm yoy second quarter
row posit sign much
character compress margin driven sever gener drug price
deflat adjust pre-tax incom per share yoy
materi outpac revenu growth appli debt
reduct share repurchas boost per share earn see
limit abil expand margin due downstream consolid
drug suppli chain improv custom purchas power expect ep
grow modestli steadi sale growth /colin scarola
pm et cfra keep hold recommend share
corpor keep target fy
sept ep forecast -- histor forward price-to-earnings averag due
view negoti power custom diminish rais fy
ep estim keep mar-q ep vs
beat consensu mar-q revenu grew yoy higher drug
volum especi strong demand specialti drug adjust gross margin
fell basi point yoy quarter solid sg expens
contain allow stabl overal oper margin consist
mar-q adjust pre-tax incom per share grew yoy materi
faster revenu prolif share repurchas last year
provid percentag point boost stabil margin welcom
develop contract throughout see limit abil
expand due downstream consolid drug suppli chain
et cfra keep hold recommend share
corpor rais target fy
sept ep forecast -- histor forward price-to-earnings averag due
margin pressur expect lower fy ep estim
dec-q ep vs met
estim report solid revenu growth yoy dec-q although
estim organ growth roughli half exclud major
acquisit despit strong sale growth quarter
full year howev adjust pre-tax incom continu declin
drop yoy dec-q main culprit shrink margin
adjust gross margin cy cy think
stabil earn move past regulatori closur
pharmedium plant see limit growth ahead
consolid amongst upstream drugmak downstream payer like
continu pressur margin side /colin scarola
amerisourcebergen corpor lower target
fy sept ep forecast discount
histor averag due growth challeng expect lower
fy ep estim start sept-q ep
 miss consensu sale yoy sept-q
aid purchas largest independ drug distributor
retail pharmaci locat acquir largest
retail pharmaci custom earlier year despit strong revenu growth
howev estim yoy reduct adj pre-tax incom
pre-tax margin fell quarter margin continu
pressur gener drug price deflat greater well
oper challeng pharmedium plant think
difficulti gener earn growth revenu growth impact
 wear think gener deflat continu /colin
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
